Today, Hovione announced that it is expanding its Cork site in Loughbeg and will create up to 100 jobs over a three-year period. The expansion in Ireland is part of a global expansion strategy representing an investment of €148 million ($170million) in increasing its capacity at its sites in Ireland, the USA and Portugal and was recently announced by Guy Villax, Chief Executive Officer, and Jean-Luc Herbeaux, Chief Operating Officer, at Hovione.
Today, Hovione announced that it is expanding its Cork site in Loughbeg and will create up to 100 jobs as part of a global €148 million expansion. Pictured are (L-R) Dr. Paul Downing, General Manager, and Mary Hennessy, Senior Human Resources Director, at Hovione in Cork. Photograph: Darragh Kane Photography
Dr. Paul Downing, General Manager at Hovione in Cork said: “Hovione in Cork is one of the strategic growth engines of the company. With its unique location in a pharmaceutical hub, our Loughbeg site plays a significant and strategic role within the global network. Hovione in Cork has expanded rapidly over the past number of years. Since it was established in 2009, it has more than quadrupled in terms of team members. We currently employ over 200 team members and this latest expansion and growth announcement will lead to a further 100 jobs.”
Senior Human Resources Director, Mary Hennessy said: “Hovione was established more than 60 years ago in Portugal with a goal to strive for excellence, rigor, innovation and quality. For over a decade, we have ensured that the Cork site has these values at the forefront of everything we do. As our growth is organic, it allows us to stay true to our culture and values. We are delighted to be expanding our operations here and are now looking for skilled personnel to join our agile, dynamic and passionate team.”
Hovione is an international company dedicated to helping pharmaceutical customers bring new and off-patent drugs to market. It has sites in Ireland (Cork), Portugal, China and the US. The Cork site facilitates the production of highly Potent Active Pharmaceutical Ingredients (HPAPI) and supports the onboarding of Drug Substance Manufacturing projects of all sizes. The expansion will fuel plans to create an ecosystem, where large customer projects can connect to the existing infrastructure and equipment. The Cork site will also receive a new commercial size spray dryer, in line with demand for particle engineering services.